Cardiovascular effects of incretins in diabetes.
Can J Diabetes
; 37(5): 309-14, 2013 Oct.
Article
em En
| MEDLINE
| ID: mdl-24500557
ABSTRACT
Recent years have seen an enormous increase in the number of therapeutic agents available for lowering blood glucose levels in people with type 2 diabetes. Among these agents, the incretin mimetics glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists and dipeptidyl peptidase 4 (DPP4) inhibitors have received particular attention for the potential of these interventions to positively impact on cardiovascular outcomes. Although the results of large-scale cardiovascular outcome trials eagerly are anticipated, an increasing body of literature from preclinical and early phase clinical studies has indicated that both GLP-1R agonists and DPP4 inhibitors may exert glucose-independent cardiovascular effects. Despite its role in glucose homeostasis, the GLP-1R is surprisingly widely distributed throughout the body, including in the heart. GLP-1 may exert its effects through both receptor-dependent and receptor-independent mechanisms and through the actions of both the intact peptide and its metabolites. In addition, DPP4 inhibition not only augments the circulating levels of incretin hormones, but it also holds the capacity to augment the activity of other biologically important substrates, most notably the small protein stromal cell-derived factor 1 alpha. Whether these collective functions will act to reduce cardiovascular events in patients remains to be determined.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Endotélio Vascular
/
Doenças Cardiovasculares
/
Miócitos Cardíacos
/
Diabetes Mellitus Tipo 2
/
Angiopatias Diabéticas
/
Peptídeo 1 Semelhante ao Glucagon
/
Incretinas
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Can J Diabetes
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Canadá